Your browser doesn't support javascript.
loading
Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant.
Cherng, Hua-Jay J; Xu, Guofan; Feng, Lei; Steiner, Raphael; Fayad, Luis; Strati, Paolo; Nair, Ranjit; Nastoupil, Loretta J; Lee, Hun Ju; Neelapu, Sattva S; Flowers, Christopher R; Rodriguez, Maria; Wang, Michael; Hagemeister, Fredrick; Pinnix, Chelsea C; Ramdial, Jeremy; Srour, Samer; Nieto, Yago; Rezvani, Katayoun; Champlin, Richard; Kebriaei, Partow; Westin, Jason; Macapinlac, Homer A; Shpall, Elizabeth; Ahmed, Sairah.
Afiliación
  • Cherng HJ; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Xu G; Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, New York, USA.
  • Feng L; Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Steiner R; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Fayad L; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Strati P; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Nair R; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Nastoupil LJ; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Lee HJ; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Neelapu SS; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Flowers CR; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Rodriguez M; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Wang M; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hagemeister F; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Pinnix CC; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ramdial J; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Srour S; Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Nieto Y; Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Rezvani K; Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Champlin R; Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kebriaei P; Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Westin J; Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Macapinlac HA; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Shpall E; Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ahmed S; Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Br J Haematol ; 200(1): 35-44, 2023 01.
Article en En | MEDLINE | ID: mdl-36068929
ABSTRACT
Salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) is a potentially curative treatment for patients with relapsed or refractory large B-cell lymphoma (rrLBCL) with chemosensitive disease. A18 F-fluorodeoxyglucose positron emission tomography (PET) scan after salvage chemotherapy is used to assess response and eligibility for ASCT, but metrics for chemosensitivity in patients with residual disease are not well defined. We performed a single-centre retrospective analysis of 92 patients with a partial response or stable disease after salvage chemotherapy for rrLBCL who received ASCT to investigate PET-derived parameters and their prognostic utility. The Deauville 5-point Scale (D-5PS) score, maximum standardised uptake value (SUVmax ), total metabolic tumour volume (TMTV), and total lesion glycolysis (TLG) were calculated from the post-salvage/pre-ASCT PET scan. The 5-year progression-free survival (PFS) and overall survival (OS) rates were 40% and 54% respectively. A D-5PS score of 5 (p = 0.0082, hazard ratio [HR] 2.09), high SUVmax (p = 0.0015, HR 2.48), TMTV (p = 0.035, HR 1.83) and TLG (p = 0.0036, HR 2.27) were associated with inferior PFS. A D-5PS score of 5 (p = 0.030, HR 1.98) and high SUVmax (p = 0.0025, HR 2.55) were associated with inferior OS. PET-derived parameters may help prognosticate outcomes after ASCT in patients with rrLBCL with residual disease after salvage chemotherapy.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Br J Haematol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Br J Haematol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos